查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1617226

2030 年肺癌药物市场预测：按类型、治疗类型、通路和地区分類的全球分析

Lung Cancer Therapeutic Market Forecasts to 2030 - Global Analysis By Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Other Types), Therapy Type, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球肺癌药物市场规模为 375 亿美元，预计到 2030 年将达到 810 亿美元，预测期内复合年增长率为 13.7%。

肺癌药物包括旨在控制和治癒肺癌（一种在肺部组织中发生的恶性）的各种治疗和介入。这些治疗包括手术、放射线治疗和化疗。标靶治疗使用蛋白酪氨酸激酶抑制剂和单株抗体等药物来针对癌细胞内的特定基因突变或异常。免疫疗法使用查核点抑制剂等药物，利用人体的免疫系统来辨识并攻击癌细胞。整合多种治疗方法的联合治疗已在疾病晚期显示出疗效。个人化医疗透过根据患者的基因谱量身订做治疗计划来支持这些治疗。

美国肺臟协会2022 年的一份报告发现，虽然这种疾病仍然是女性和男性癌症死亡的第一大原因，但过去5 年全国的存活率从21% 增加到25%，但仍显着低于20%。

肺癌发生率增加

肺癌患者数量的不断增加，对多种治疗方法，包括手术、化疗、放射线治疗、标靶治疗、免疫治疗等。此外，对诊断工具和影像技术等早期检测和筛检解决方案的需求也在不断增长。这些工具在早期检测肺癌和确定最有效的治疗策略方面发挥着重要作用。这种需求正在导致市场成长并增加製药公司和医疗保健提供者的收益。

副作用和功效问题

肺癌治疗通常与严重的副作用有关，例如噁心、疲劳、免疫抑制和器官毒性，这些副作用可能会降低患者的依从性和次优的治疗结果。如果这些治疗无法产生预期的结果或疾病进展有限，患者和医疗保健提供者可能不愿意继续治疗，导致治疗中断率很高，并且需要可能更昂贵的替代治疗，阻碍市场成长。

医学研究进展

基因组学和分子生物学的发展导致了针对具有特定基因突变的癌细胞的标靶治疗的发展，与传统化疗相比，提高了疗效并减少了副作用。免疫疗法，例如免疫查核点抑制剂，有可能显着改变非小细胞肺癌的治疗模式，增强人体的免疫反应并延长存活期。此外，精准医疗可以根据患者独特的癌症类型和基因组成製定个人化治疗计划，从而推动市场成长。

治疗费用高

肺癌治疗的高昂费用是一种经济负担，尤其是对于没有保险的患者来说，导致治疗延迟或错过、健康结果不佳以及存活率较低。这加剧了健康不平等，因为低收入和用户不太可能获得所需的治疗。因此，肺癌治疗的经济负担显着影响患者的福祉和医疗保健系统的效率。

COVID-19 的影响

COVID-19大流行对肺癌药物市场产生了重大影响，由于医疗保健系统的压力和患者的犹豫，导致诊断和治疗中断。选择性治疗被推迟，降低了早期发现率和治疗启动率。临床试验被推迟或面临招募问题，减缓了药物开发。然而，大流行加速了远端医疗和数位医疗解决方案的采用，这在一定程度上缓解了治疗中断的情况。

免疫治疗领域预计将成为预测期内最大的市场

免疫查核点抑制剂，如Pembrolizumab和纳武单抗，是治疗非小细胞肺癌（NSCLC）的关键成分，可提高存活率并成为晚期护理标准，使其成为免疫治疗领域的重要组成部分。事实证明，免疫疗法与化疗、标靶治疗和其他药物的组合在某些患者群体中比单一疗法更有效，可以改善患者的预后。

预计医院药学产业在预测期内将经历最高的复合年增长率。

预计医院药房业务在预测期内将以最高的复合年增长率成长。由于医院药局经常参与临床试验，因此可以儘早获得新的治疗方法，并将最新的治疗方法引入临床实践。此外，从这些业务中收集的资料有助于了解治疗效果和患者结果，影响未来的药物开发和市场需求。

比最大的地区

在预测期内，北美，尤其是美国，预计将占据最大的市场占有率，因为该地区製药公司和研究机构高度集中，并且是创新肺癌治疗药物开发和核准的主要企业。 FDA 和加拿大卫生署等关键监管机构的存在促进了新药的快速核准和推出，使北美成为尖端癌症药物的中心。

复合年增长率最高的地区：

预计亚太地区在预测期内将实现最高的复合年增长率。同时，亚太地区，特别是富裕国家，越​​来越多地将标靶治疗和免疫疗法等先进治疗纳入标准治疗方案。然而，肺癌治疗的可用性因地区而异，日本和韩国等已开发国家比印度和印尼等低收入国家更容易获得创新治疗方法，但存活率较低，这可能会影响治疗结果。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球肺癌药物市场：依类型

  • 非小细胞肺癌
    • 腺癌
    • 鳞状细胞癌
    • 大细胞癌
  • 小细胞肺癌
  • 其他类型

第六章全球肺癌药物市场：依治疗类型

  • 免疫疗法
    • Durvalumab
    • 纳武单抗
    • Atezolizumab
    • Pembrolizumab
  • 标靶治疗
    • Bevacizumab
    • Dabrafenib/曲美替尼
    • Erlotinib
    • Osimertinib
    • 其他标靶治疗
  • 化疗
  • 放射治疗
  • 其他治疗方法

第七章全球肺癌药物市场：依分销管道划分

  • 零售药房
  • 医院药房
  • 网路药房
  • 专业癌症治疗中心
  • 其他分销管道

第八章全球肺癌药物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、合作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第 10 章 公司概况

  • Abbvie
  • Amgen Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Genentech
  • Hoffmann-La Roche
  • Johnson & Johnson
  • Merck & Co.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC28106

According to Stratistics MRC, the Global Lung Cancer Therapeutics Market is accounted for $37.5 billion in 2024 and is expected to reach $81.0 billion by 2030 growing at a CAGR of 13.7% during the forecast period. Lung cancer therapeutics encompasses various treatments and interventions aimed at managing or curing lung cancer, a malignancy originating in lungs' tissues. These treatments include surgery, radiation therapy, and chemotherapy. Targeted therapies focus on specific genetic mutations or abnormalities in cancer cells, using drugs like tyrosine kinase inhibitors and monoclonal antibodies. Immunotherapy uses the body's immune system to recognize and attack cancer cells, often through checkpoint inhibitors. Combination therapies, integrating various treatment modalities, have shown efficacy in advanced stages of the disease. Personalized medicine supports these treatments by tailoring treatment plans based on the patient's genetic profile.

According to the 2022 report by the American Lung Association, while the disease remains the leading cause of cancer deaths among women and men, the survival rate over the past five years has increased from 21% nationally to 25% yet remains significantly lower among communities of colour at 20%.

Market Dynamics:

Driver:

Increasing incidence of lung cancer

The rise in lung cancer cases has fueled a surge in demand for various treatment options, including surgeries, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Moreover the demand for early detection and screening solutions, such as diagnostic tools and imaging technologies, is also growing, as these tools play a crucial role in identifying lung cancer early and determining the most effective treatment course. This demand has led to market growth and increased revenue for pharmaceutical companies and healthcare providers.

Restraint:

Side effects and efficacy concerns

Lung cancer treatments often have severe side effects like nausea, fatigue, immune suppression, and organ toxicity, which can reduce patient adherence and lead to suboptimal outcomes. If these treatments don't yield expected results or have limited disease progression, patients and healthcare providers may hesitate to continue, resulting in higher treatment discontinuation rates and the need for alternative, potentially more expensive, treatments hampering the market growth.

Opportunity:

Advancements in medical research

Advances in genomics and molecular biology have led to the development of targeted therapies targeting cancer cells with specific genetic mutations, improving efficacy and reducing side effects compared to traditional chemotherapy. Immunotherapy, such as immune checkpoint inhibitors, has significantly changed the treatment landscape for NSCLC, enhancing the body's immune response and potentially extending survival. In addition precision medicine has enabled personalized treatment plans based on a patient's specific cancer type and genetic makeup encourages the growth of the market.

Threat:

High treatment costs

High lung cancer treatment costs can cause financial burdens for patients, especially those without insurance, leading to delayed or missed treatment, poorer health outcomes, and reduced survival rates. This exacerbates health inequities, as low-income or underinsured populations are less likely to receive necessary care. Consequently, the economic burden of lung cancer therapy significantly impacts patient well-being and healthcare system efficiency.

Covid-19 Impact

The COVID-19 pandemic had a notable impact on the Lung Cancer Therapeutics Market, leading to disruptions in diagnosis and treatment due to healthcare system strains and patient hesitancy. Elective procedures were delayed, reducing early detection and treatment initiation rates. Clinical trials were postponed or faced recruitment challenges, slowing drug development. However, the pandemic accelerated the adoption of telemedicine and digital health solutions, which partially mitigated treatment interruptions.

The immunotherapy segment is expected to be the largest during the forecast period

The immunotherapy segment is projected to account for the largest market share during the projection period owing to particularly immune checkpoint inhibitors like pembrolizumab and nivolumab, is a key component in treating non-small cell lung cancer (NSCLC), improving survival rates and becoming the standard treatment for advanced stages. Combining immunotherapy with chemotherapy, targeted therapy, or other agents has proven more effective than monotherapy for certain patient groups, improving patient outcomes.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

During the projection period, the hospital pharmacies segment is expected to grow at the highest CAGR because hospital pharmacies often participate in clinical trials, providing early access to new therapies and integrating the latest treatment options into clinical practice. Additionally the data collected from these operations can help understand treatment efficacy and patient outcomes, influencing future drug development and market demand.

Region with largest share:

During the estimation period, the North America region is expected to capture the largest market share owing to North America, particularly the U.S., is leading in drug development and approval of innovative lung cancer treatments, with a high concentration of pharmaceutical companies and research institutions. The presence of major regulatory bodies like the FDA and Health Canada facilitates quick approval and introduction of new drugs, making North America a hub for cutting-edge cancer therapeutics.

Region with highest CAGR:

The Asia Pacific region is projected to achieve the highest CAGR during the forecast period because Asia Pacific region is increasingly incorporating advanced therapies like targeted therapies and immunotherapy into standard treatment protocols, particularly in wealthier countries. However, there is variability in lung cancer therapeutic availability across the region, with developed countries like Japan and South Korea having more access to innovative treatments than lower-income nations like India and Indonesia, which can affect survival rates and treatment outcomes.

Key players in the market

Some of the key players in Lung Cancer Therapeutics market include Abbvie , Amgen Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genentech, Hoffmann-La Roche, Johnson & Johnson, Merck & Co., Millennium Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Sanofi and Teva Pharmaceutical Industries Ltd.

Key Developments:

In November 2024, Novartis announced that the European Commission (EC) has approved Kisqali(R) (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence.

In June 2024, AbbVie announced the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study for the treatment of IBD.

Types Covered:

  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Other Types

Therapy Types Covered:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Radiotherapy
  • Other Therapy Types

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Specialty Cancer Treatment Centers
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Lung Cancer Therapeutics Market, By Type

  • 5.1 Introduction
  • 5.2 Non-Small Cell Lung Cancer
    • 5.3.1 Adenocarcinoma
    • 5.3.2 Squamous Cell Carcinoma
    • 5.3.3 Large Cell Carcinoma
  • 5.3 Small Cell Lung Cancer
  • 5.4 Other Types

6 Global Lung Cancer Therapeutics Market, By Therapy Type

  • 6.1 Introduction
  • 6.2 Immunotherapy
    • 6.2.1 Durvalumab
    • 6.2.2 Nivolumab
    • 6.2.3 Atezolizumab
    • 6.2.4 Pembrolizumab
  • 6.3 Targeted Therapy
    • 6.3.1 Bevacizumab
    • 6.3.2 Dabrafenib/trametinib
    • 6.3.3 Erlotinib hydrochloride
    • 6.3.4 Osimertinib
    • 6.3.5 Other Targeted Therapies
  • 6.4 Chemotherapy
  • 6.5 Radiotherapy
  • 6.6 Other Therapy Types

7 Global Lung Cancer Therapeutics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacies
  • 7.3 Hospital Pharmacies
  • 7.4 Online Pharmacies
  • 7.5 Specialty Cancer Treatment Centers
  • 7.6 Other Distribution Channels

8 Global Lung Cancer Therapeutics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbvie
  • 10.2 Amgen Inc.
  • 10.3 AstraZeneca
  • 10.4 Boehringer Ingelheim
  • 10.5 Bristol-Myers Squibb Company
  • 10.6 Celgene Corporation
  • 10.7 Eli Lilly and Company
  • 10.8 Genentech
  • 10.9 Hoffmann-La Roche
  • 10.10 Johnson & Johnson
  • 10.11 Merck & Co.
  • 10.12 Millennium Pharmaceuticals, Inc.
  • 10.13 Novartis AG
  • 10.14 Pfizer Inc.
  • 10.15 Sanofi
  • 10.16 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Lung Cancer Therapeutics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Lung Cancer Therapeutics Market Outlook, By Type (2022-2030) ($MN)
  • Table 3 Global Lung Cancer Therapeutics Market Outlook, By Non-Small Cell Lung Cancer (2022-2030) ($MN)
  • Table 4 Global Lung Cancer Therapeutics Market Outlook, By Adenocarcinoma (2022-2030) ($MN)
  • Table 5 Global Lung Cancer Therapeutics Market Outlook, By Squamous Cell Carcinoma (2022-2030) ($MN)
  • Table 6 Global Lung Cancer Therapeutics Market Outlook, By Large Cell Carcinoma (2022-2030) ($MN)
  • Table 7 Global Lung Cancer Therapeutics Market Outlook, By Small Cell Lung Cancer (2022-2030) ($MN)
  • Table 8 Global Lung Cancer Therapeutics Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 9 Global Lung Cancer Therapeutics Market Outlook, By Therapy Type (2022-2030) ($MN)
  • Table 10 Global Lung Cancer Therapeutics Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 11 Global Lung Cancer Therapeutics Market Outlook, By Durvalumab (2022-2030) ($MN)
  • Table 12 Global Lung Cancer Therapeutics Market Outlook, By Nivolumab (2022-2030) ($MN)
  • Table 13 Global Lung Cancer Therapeutics Market Outlook, By Atezolizumab (2022-2030) ($MN)
  • Table 14 Global Lung Cancer Therapeutics Market Outlook, By Pembrolizumab (2022-2030) ($MN)
  • Table 15 Global Lung Cancer Therapeutics Market Outlook, By Targeted Therapy (2022-2030) ($MN)
  • Table 16 Global Lung Cancer Therapeutics Market Outlook, By Bevacizumab (2022-2030) ($MN)
  • Table 17 Global Lung Cancer Therapeutics Market Outlook, By Dabrafenib/trametinib (2022-2030) ($MN)
  • Table 18 Global Lung Cancer Therapeutics Market Outlook, By Erlotinib hydrochloride (2022-2030) ($MN)
  • Table 19 Global Lung Cancer Therapeutics Market Outlook, By Osimertinib (2022-2030) ($MN)
  • Table 20 Global Lung Cancer Therapeutics Market Outlook, By Other Targeted Therapies (2022-2030) ($MN)
  • Table 21 Global Lung Cancer Therapeutics Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 22 Global Lung Cancer Therapeutics Market Outlook, By Radiotherapy (2022-2030) ($MN)
  • Table 23 Global Lung Cancer Therapeutics Market Outlook, By Other Therapy Types (2022-2030) ($MN)
  • Table 24 Global Lung Cancer Therapeutics Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 25 Global Lung Cancer Therapeutics Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 26 Global Lung Cancer Therapeutics Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 27 Global Lung Cancer Therapeutics Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 28 Global Lung Cancer Therapeutics Market Outlook, By Specialty Cancer Treatment Centers (2022-2030) ($MN)
  • Table 29 Global Lung Cancer Therapeutics Market Outlook, By Other Distribution Channels (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.